Literature DB >> 9445031

STP and Tip are essential for herpesvirus saimiri oncogenicity.

S M Duboise1, J Guo, S Czajak, R C Desrosiers, J U Jung.   

Abstract

Mutant forms of herpesvirus saimiri (HVS) subgroup C strain 488 with deletions in either STP-C488 or Tip were constructed. The transforming potentials of the HVS mutants were tested in cell culture and in common marmosets. Parental HVS subgroup C strain 488 immortalized common marmoset T lymphocytes in vitro to interleukin-2-independent growth, but neither of the deletion mutants produced such growth transformation. Wild-type HVS produced fatal lymphoma within 19 to 20 days of experimental infection of common marmosets, while HVS deltaSTP-C488 and HVS deltaTip were nononcogenic. Virus was repeatedly isolated from the peripheral blood of marmosets infected with mutant virus for more than 5 months. These results demonstrate that STP-C488 and Tip are not required for replication or persistence, but each is essential for transformation in cell culture and for lymphoma induction in common marmosets.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445031      PMCID: PMC124609     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  In vitro immortalization of marmoset cells with three subgroups of herpesvirus saimiri.

Authors:  E Szomolanyi; P Medveczky; C Mulder
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Deletion mutants of herpesvirus saimiri define an open reading frame necessary for transformation.

Authors:  S C Murthy; J J Trimble; R C Desrosiers
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

3.  Isolation of Herpesvirus saimiri from blood of squirrel monkeys (Saimiri sciureus).

Authors:  L A Falk; L G Wolfe; F Deinhardt
Journal:  J Natl Cancer Inst       Date:  1972-05       Impact factor: 13.506

4.  Classification of herpesvirus saimiri into three groups based on extreme variation in a DNA region required for oncogenicity.

Authors:  P Medveczky; E Szomolanyi; R C Desrosiers; C Mulder
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

5.  Deletion of DNA sequence in a nononcogenic variant of Herpesvirus saimiri.

Authors:  J M Koomey; C Mulder; R L Burghoff; B Fleckenstein; R C Desrosiers
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

6.  A region of the Herpesvirus saimiri genome required for oncogenicity.

Authors:  R C Desrosiers; A Bakker; J Kamine; L A Falk; R D Hunt; N W King
Journal:  Science       Date:  1985-04-12       Impact factor: 47.728

7.  Nononcogenic deletion mutants of herpesvirus saimiri are defective for in vitro immortalization.

Authors:  R C Desrosiers; D P Silva; L M Waldron; N L Letvin
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

8.  Enhanced downregulation of Lck-mediated signal transduction by a Y114 mutation of herpesvirus Saimiri tip.

Authors:  J Guo; M Duboise; H Lee; M Li; J K Choi; M Rosenzweig; J U Jung
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Herpesvirus saimiri strains from three DNA subgroups have different oncogenic potentials in New Zealand white rabbits.

Authors:  M M Medveczky; E Szomolanyi; R Hesselton; D DeGrand; P Geck; P G Medveczky
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

10.  Construction of replication-competent Herpesvirus saimiri deletion mutants.

Authors:  R C Desrosiers; R L Burghoff; A Bakker; J Kamine
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

View more
  42 in total

Review 1.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  Evolutionary aspects of oncogenic herpesviruses.

Authors:  J Nicholas
Journal:  Mol Pathol       Date:  2000-10

3.  Transcriptional regulation of the K1 gene product of Kaposi's sarcoma-associated herpesvirus.

Authors:  Brian S Bowser; Scott M DeWire; Blossom Damania
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Herpesvirus saimiri vFLIP provides an antiapoptotic function but is not essential for viral replication, transformation, or pathogenicity.

Authors:  D Glykofrydes; H Niphuis; E M Kuhn; B Rosenwirth; J L Heeney; J Bruder; G Niedobitek; I Müller-Fleckenstein; B Fleckenstein; A Ensser
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Immortalization of human and rhesus macaque primary antigen-specific T cells by retrovirally transduced telomerase reverse transcriptase.

Authors:  Eugene V Barsov
Journal:  Curr Protoc Immunol       Date:  2011-11

6.  Altered dynamics in Lck SH3 upon binding to the LBD1 domain of Herpesvirus saimiri Tip.

Authors:  David D Weis; Peter Kjellen; Bartholomew M Sefton; John R Engen
Journal:  Protein Sci       Date:  2006-10       Impact factor: 6.725

7.  Functional characterization and conformational analysis of the Herpesvirus saimiri Tip-C484 protein.

Authors:  Jennifer L Mitchell; Ronald P Trible; Lori A Emert-Sedlak; David D Weis; Edwina C Lerner; Jeremy J Applen; Bartholomew M Sefton; Thomas E Smithgall; John R Engen
Journal:  J Mol Biol       Date:  2006-12-16       Impact factor: 5.469

Review 8.  Emerging Role of Retromer in Modulating Pathogen Growth.

Authors:  Cherilyn Elwell; Joanne Engel
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

9.  Activation of the STAT6 transcription factor in Jurkat T-cells by the herpesvirus saimiri Tip protein.

Authors:  Yuri Kim; Eun-Kyung Kwon; Ju-Hong Jeon; Insuk So; In-Gyu Kim; Myung-Sik Choi; Ik-Sang Kim; Joong-Kook Choi; Jae Ung Jung; Nam-Hyuk Cho
Journal:  J Gen Virol       Date:  2011-10-19       Impact factor: 3.891

10.  Herpesvirus ateles Tio can replace herpesvirus saimiri StpC and Tip oncoproteins in growth transformation of monkey and human T cells.

Authors:  Jens-Christian Albrecht; Brigitte Biesinger; Ingrid Müller-Fleckenstein; Doris Lengenfelder; Monika Schmidt; Bernhard Fleckenstein; Armin Ensser
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.